Anush

Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines

Abstract:

Furo(thieno)[2,3-b]pyridines are “privileged medicinal scaffolds”, used for the development of pharmaceutical agents, showing a wide range of pharmacological activities. Their annulated derivatives attracted big interest of the scientific community due to their broad spectrum of biological activities among which are the inhibition of phosphodiesterase, antiproliferative and antimicrobial activities. Some of our recent data on fused derivatives of furo(thieno)[2,3-b]pyridines also indicate that these compounds have high biological activity. In particular, among the tricyclic furo(thieno)[2,3-b]pyridines, a compound with unprecedented high antiviral activity was discovered, which can be an effective drug against African swine fever. Among the N- and S-alkyl derivatives of tetracyclic pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]­pyrimidines some compounds were found that showed higher antibacterial and antifungal activity against some strains than comparative drugs: ampicillin, ketoconazole and bifonazole. Some of amino derivatives of pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimidines, were found to possess higher antitumor activity than the well-known drug doxorubicin. Continuing our research in this area, new unique heterocyclic systems: pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines have been synthesized with the expectation of discovering more active compounds among them.

Audience Take Away Notes:

• In my work the synthesis of new heterocyclic compounds is described, which are currently not known in the literature, therefore It is a new knowledge in the chemistry of heterocyclic compounds
• The audience will receive new information in the field of heterocyclic chemistry and can use it in their teaching practice
• The information will also be of interest to synthetic organic chemists, computational biology researchers, and pharmaceutical companies

Biography:

Dr. Anush studied Chemistry at the Yerevan State University, Armenia and graduated as MS in 2011. Since 2009 she joined the research group of Prof. Samvel Sirakanyan at the Institute of Fine Organic Chemistry of Scientific Technological Center of Organic and Pharmaceutical Chemistry, Republic of Armenia, Armenian National Academy of Science (STC OPC NAS RA, IFOC). She received her PhD degree in 2013 at the same institution. She has published more than 45 research articles in SCI(E) journals. In 2018 she received RA Presidential award for the series of articles.